Presenter: Alexandra Vamvakidou-Thomas, Ph.D
Sr. Field Application Scientist, Regional Marketing
Identification of breast cancer biomarkers for relapse is important for developing individualized therapies covering a range of interventions from tumor excision, standard chemotherapy to vaccine therapy. Breast cancer is a clinically, genetically and morphologically heterogeneous disease. Early detection and diagnosis is crucial to survival outcome. Pathologists consider several prognostic factors characteristic for breast tumors, such as hormone receptor status, lymph node involvement and histological tumor grade prior to prescribing a course of treatment. Proteins used in cell communication and signaling are potential biomarkers for a number of disease states involving inflammation, and cancer. In order to identify potential biomarkers of relapse in breast cancer, we have analyzed relapse related microarray data. We have identified a list of significantly altered genes that are significantly enriched in breast cancer relapse cases.
The present study shows how TIBCO Spotfire® can be applied to scientific research, integrating genomics and patient profiles for an optimal separation of patients with good and poor outcomes. Moreover, numerous multigene signatures associated with prognosis and response to therapies have emerged and we will compare publically available data to these discriminatory gene expression signatures.
Click Here to check the complete line-up of Spotfire Webinars.